Xenetic Logo

3-0.jpg
  • Home
  • About Us
  • Science & Technology
  • Product Pipeline
    • PolyXen product pipeline
    • ImuXen product pipeline
    • Oncohist
    • Research & Development
    • Patents/Intellectual Property
  • Investor Relations
  • Careers
Product Pipeline
Patents/Intellectual Property

Xenetic has strong intellectual property protection surrounding all of its proprietary technologies.  We continuously strive to identify and protect novel technologies and methodologies arising from our research efforts.

Below are links to examples of key granted patents and published patent applications. 

Geographic coverage of granted patents may extend to territories other than in the example shown.


Polyxen Technology Area

Activated sialic acid derivatives (WO application)
Derivatisation of proteins (EU, granted)
Endotoxin reduction in PSA (WO, application)
Glycopolysialylation (WO, application)
Maleimide PSA derivatives (EU, granted)
NHS amino PSA derivatives (US, granted)
N-terminal polysialylation (WO, application)
Polysaccharide fractionation (WO, application)
Polysaccharides and drug delivery systems (EU, granted)
Polysialylated EPO (WO, application)
Polysialylated GCSF (EU, granted)
Sialic acid derivatives (US, granted)

ImuXen Technology Area

Capisomes (EU, granted)
Liposomal co-delivery vaccines (EU, granted)
Liposomal gene vaccines (EU, granted)
Liposomal polysaccharide and protein vaccines (WO, application)
Liposomal siRNA delivery (WO, application)
Multivalent liposomal polysaccharide and protein vaccines (WO, application)
Oral liposomal vaccines (EU, granted)
 
  • Sitemap
  • Accessibility
  • Terms and Conditions
  • Error
EmailPrint

Xenetic Biosciences plc © 2011 Designed and developed by Emperor